Science Corporation Implants Vision-Restoring Chip PRIMA in First Stargardt Disease Patient

Science Corporation CEO Max Hodak announced that the company implanted its vision-restoring chip, PRIMA, into its first patient with Stargardt disease, an inherited eye disease affecting approximately 150,000 people worldwide. The patient saw a letter during the first rehabilitation session and read a word during the second. PRIMA is commercially available in Europe for geographic atrophy, an advanced form of age-related macular degeneration, and the implant, a two by two millimeter device, functions as artificial photoreceptors, transmitting a view via camera-equipped glasses to restore sharp, high-contrast, black and white central vision, though the field of view is currently limited.